| [1] |
Oe Y, Nakaya I, Yahata M, et al. A case of gamma1-heavy chain deposition disease successfully treated with melphalan and prednisolone therapy [J]. Intern Med, 2010, 49(14): 1411-1415.
|
| [2] |
Chang IJ, Cheunsuchon B, Miller FJ, et al. A 66-year-old woman with progressive renal insufficiency, nephrotic syndrome, and monoclonal protein [J]. Am J Kidney Dis, 2003, 41(2): 508-517.
|
| [3] |
Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease [J]. Kidney Int, 2004, 65(2): 642-648.
|
| [4] |
Oe Y, Soma J, Sato H, et al. Heavy chain deposition disease: an overview [J]. Clin Exp Nephrol, 2013, 17(6): 771-778.
|
| [5] |
Rane S, Rana S, Mudrabettu C, et al. Heavy-chain deposition disease: a morphological, immunofluorescence and ultrastructural assessment [J]. Clin Kidney J, 2012, 5(5): 383-389.
|
| [6] |
Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum [J]. J Am Soc Nephrol, 2001, 12(7): 1482-1492.
|
| [7] |
Pérez-Suárez G, Raya JM, Alvarez A, et al. Progressive renal failure as the first manifestation of monoclonal light-chain deposition disease with rapid multiple organ involvement [J]. Clin Nephrol, 2009, 71(3): 314-317.
|
| [8] |
Comenzo RL, Wally J, Kica G, et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation [J]. Br J Haematol, 1999, 106(3): 744-751.
|
| [9] |
Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL) [J]. Blood, 2003, 101(10): 3801-3808.
|
| [10] |
Varga C, Titus SE, Toskic D, et al. Use of novel therapies in the treatment of light chain amyloidosis [J]. Blood Rev, 2019, 37: 100581.
|
| [11] |
Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine [J]. N Engl J Med, 1997, 336(17): 1202-1207.
|
| [12] |
Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [J]. N Engl J Med, 2007, 357(11): 1083-1093.
|
| [13] |
Dispenzieri A. Renal risk and response in amyloidosis [J]. Blood, 2014, 124(15): 2315-2316.
|
| [14] |
Pozzi C, D′Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors [J]. Am J Kidney Dis, 2003, 42(6): 1154-1163.
|
| [15] |
Heilman RL, Velosa JA, Holley KE, et al. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease [J]. Am J Kidney Dis, 1992, 20(1): 34-41.
|